Research Summary

My research focuses on immunotherapy in cancer with a special focus on skin cancers such as melanoma. I have designed and conducted numerous Phase I and II clinical trials. A collaboration with Dr Richard Heller has resulted in intratumoral IL12 as a treatment for melanoma. At UCSF, I co-direct the melanoma program and am the PI of several early phase and melanoma specific clinical trials as well as collaborating with my colleagues Michael Rosenblum, Max Krummel, Matt Spitzer and Jeff Bluestone at UCSF as well as other national experts in melanoma patients progressing on immunotherapy. One of the areas I am interested in is immunotherapy with PD-1 antibodies and in understanding resistance to PD-1 especially site specific immunity.

Education

1987-1990, Postdoctoral Fellow, Laboratory of F. Merlin Bumpus, PhD and Ahsan Husain, PhD, Cleveland Clinic Foundation, Cleveland, OH
1990-1994, Research Assistant Staff, Laboratory of Loren Field, PhD, Krannert Institute of Cardiology. Indiana University Medical Center, Indianapolis, IN
1994-1997, Internship and Residency in Internal Medicine, Indiana University Medical Center, Indianapolis, IN
1997-2000, Fellowship in Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY

Honors & Awards

  • 1986
    Honors in Pediatrics, Government Medical College, Nagpur, India
  • 2000
    Young Investigator Award, American Society for Clinical Oncology for project "Regulation of mRNA stability by Elongation factor I."
  • 2005-2007
    Clinical Trial Award: Highest Number of Patients Enrolled in clinical trials at Moffitt Cancer Center
  • 2007-2010
    Best Doctors in America Award, Castle Connolly

Selected Publications

  1. Haugh AM, Daud AI. Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events. J Clin Invest. 2024 Oct 15; 134(20).  View on PubMed
  2. Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance AM, Daud AI, Hamid O, Larkin J, Yao L, Singh R, Lal R, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024 Dec; 35(12):1191-1199.  View on PubMed
  3. Quandt Z, Jacob S, Fadlullah MZH, Wu C, Wu C, Huppert L, Levine LS, Sison P, Tsai KK, Chow M, Kang JH, Hwang J, Lee JC, Oglesby A, Venegas J, Brintz BJ, Tan AC, Anderson MS, Rosenblum MD, Young A, Daud AI. Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response. BJC Rep. 2024 Jun 24; 2(1):46.  View on PubMed
  4. Haugh AM, Osorio RC, Francois RA, Tawil ME, Tsai KK, Tetzlaff M, Daud A, Vasudevan HN. Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations. Cancers (Basel). 2024 Mar 29; 16(7).  View on PubMed
  5. Wong P, Wisneski AD, Tsai KK, Chang TT, Hirose K, Nakakura EK, Daud AI, Maker AV, Corvera CU. Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors. World J Surg Oncol. 2024 Mar 11; 22(1):77.  View on PubMed
  6. Haugh AM, Daud AI. Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma. Cancer J. 2024 Mar-Apr 01; 30(2):108-112.  View on PubMed
  7. Feichtenschlager V, Chen L, Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Fewings E, Lee A, Chen C, Callanan C, Lin K, Qu T, Hohlova D, Vujic M, Hwang Y, Lai K, Chen S, Nguyen T, Muñoz DP, Kohwi Y, Posch C, Daud A, Rappersberger K, Kohwi-Shigematsu T, Coppé JP, Ortiz-Urda S. The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma. Mol Cancer. 2024 02 22; 23(1):40.  View on PubMed
  8. Haugh A, Daud AI. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. Am J Clin Dermatol. 2024 May; 25(3):407-419.  View on PubMed
  9. Feichtenschlager V, Chen L, Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Fewings E, Lee A, Chen C, Callanan C, Lin K, Qu T, Hohlova D, Vujic M, Hwang Y, Lai K, Chen S, Nguyen T, Muñoz DP, Kohwi Y, Posch C, Daud A, Rappersberger K, Kohwi-Shigematsu T, Coppé JP, Ortiz-Urda S. The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma. Res Sq. 2023 Dec 01.  View on PubMed
  10. Standiford TC, Patel NN, Singh A, Gochman G, Jamie Wu T, Daud AI, Goldberg AN. Pembrolizumab-associated chronic rhinosinusitis: A new endotype and management considerations. Int Forum Allergy Rhinol. 2023 Dec; 13(12):2248-2251.  View on PubMed
  11. Haugh A, Daud A. Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I? Cancer Immunol Res. 2023 07 05; 11(7):864.  View on PubMed
  12. Campana LG, Daud A, Lancellotti F, Arroyo JP, Davalos RV, Di Prata C, Gehl J. Pulsed Electric Fields in Oncology: A Snapshot of Current Clinical Practices and Research Directions from the 4th World Congress of Electroporation. Cancers (Basel). 2023 Jun 25; 15(13).  View on PubMed
  13. Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance A, Daud AI, Hamid O, Larkin J, Anderson J, Krepler C, Grebennik D, Long GV. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. J Clin Oncol. 2023 08 20; 41(24):3998-4003.  View on PubMed
  14. Rasco DW, Medina T, Corrie P, Pavlick AC, Middleton MR, Lorigan P, Hebert C, Plummer R, Larkin J, Agarwala SS, Daud AI, Qiu J, Bozon V, Kneissl M, Barry E, Olszanski AJ. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2023 07; 92(1):15-28.  View on PubMed
  15. de Braud F, Dooms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA, Gil-Bazo I, Kato S, Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A, Kim J, Caponigro G, Couillebault XM, Evans H, Campbell CD, Basu S, Moschetta M, Daud A. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. J Clin Oncol. 2023 05 10; 41(14):2651-2660.  View on PubMed
  16. Li Y, Flavell RR, Juarez R, Chow M, Wu C, Tsai K, Daud A, Behr SC. Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. Clin Radiol. 2023 02; 78(2):e131-e136.  View on PubMed
  17. Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. Immunity. 2022 Sep 13; 55(9):1749.  View on PubMed
  18. Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. Melanoma risk during immunomodulating treatment. Melanoma Res. 2022 12 01; 32(6):411-418.  View on PubMed
  19. Han M, Nguyen B, Lee JY, Browning E, Zhang J, Mukhopadhyay A, Gujar R, Salazar J, Hermiz R, Svenson L, Rolig AS, Redmond WL, Algazi AP, Daud AI, Canton DA, Twitty CG. Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity. Mol Cancer Res. 2022 06 03; 20(6):983-995.  View on PubMed
  20. Huppert LA, Daud AI. Intratumoral therapies and in-situ vaccination for melanoma. Hum Vaccin Immunother. 2022 05 31; 18(3):1890512.  View on PubMed

Go to UCSF Profiles, powered by CTSI